TI 7006

Drug Profile

TI 7006

Alternative Names: MAR-TriTE/ESO1; TI-7006

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Timmune Biotech
  • Class Antibodies; Recombinant fusion proteins
  • Mechanism of Action CD274 antigen inhibitors; Immunostimulants; Major histocompatibility complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 14 Sep 2017 Early research in Cancer in China (Parenteral) before September 2017 (Timmune Biotech pipeline, September 2017)
  • 14 Sep 2017 Timmune Biotech plans a phase I trial for Cancer in 2018 (Timmune Biotech pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top